Search

Your search keyword '"Segovia Cubero, J"' showing total 217 results

Search Constraints

Start Over You searched for: Author "Segovia Cubero, J" Remove constraint Author: "Segovia Cubero, J"
217 results on '"Segovia Cubero, J"'

Search Results

4. Updates from the International Consortium on Primary Graft Dysfunction: An Interim Report and Important Themes

5. Impact of the 2018 UNOS Allocation Change on Severe Primary Graft Dysfunction: A Report from the International Consortium on PGD

6. Validation of a Machine Learning Primary Graft Dysfunction Risk Score in a Contemporary Heart Transplant Cohort: An Analysis of the International Consortium on PGD

7. Mitigating Risk by Using the Primary Graft Dysfunction-Artificial Intelligence (PGD-AI) Calculator in a Contemporary Toronto Cohort: An Analysis from The International Consortium on PGD

8. Comparative Regional Analysis of Severe Primary Graft Dysfunction: Insights from Tthe International Consortium on PGD

9. Role of NTproBNP and donor-derived cell-free DNA in the diagnosis of acute rejection in heart transplant recipients: a prospective study

10. Donor-derived cell-free DNA as a new biomarker for acute rejection in heart transplant recipients: results from the freedna car study

11. Donor-derived cell-free DNA kinetics in the first year post-transplant in patients without acute cellular rejection

12. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

14. (1006) Donor-Derived Cell-Free DNA as a Potential Biomarker for Acute Cellular Rejection Surveillance (FreeDNA-CAR Study)

15. Incidence and Predictors of Vasoplegia after Heart Transplantation: Results from the International PGD Consortium

16. Left bundle branch pacing after transcatheter aortic valve implantation. Initial experience of a center

17. Clinical utility of the SCAI classification in cardiogenic shock patients of any etiology treated by a multidisciplinary team

18. Changes over the years in the indication for heart-lung transplantation in Spain

20. (770) - Comparative Regional Analysis of Severe Primary Graft Dysfunction: Insights from Tthe International Consortium on PGD

21. (768) - Mitigating Risk by Using the Primary Graft Dysfunction-Artificial Intelligence (PGD-AI) Calculator in a Contemporary Toronto Cohort: An Analysis from The International Consortium on PGD

22. (326) - Impact of the 2018 UNOS Allocation Change on Severe Primary Graft Dysfunction: A Report from the International Consortium on PGD

23. (285) - Sex Based Differences in Severe Primary Graft Dysfunction: An Analysis from the International Consortium on PGD

24. (122) - Updates from the International Consortium on Primary Graft Dysfunction: An Interim Report and Important Themes

25. (124) - Validation of a Machine Learning Primary Graft Dysfunction Risk Score in a Contemporary Heart Transplant Cohort: An Analysis of the International Consortium on PGD

26. Validation of the patient assessment of chronic illness care (PACIC) short form scale in heart transplant recipients: the international cross-sectional bright study

27. Utilidad de las escalas de gravedad en la predicción de mortalidad intrahospitalaria en el shock cardiogénico. Propuesta de un nuevo modelo pronóstico

29. Infective endocarditis after transcatheter aortic valve implantation

30. Cardiac allograft vasculopathy and acute rejection surveillance in the same procedure through a single vascular access. High volume center experience

34. Impact of intrapatient blood level variability of calcineurin inhibitors on heart transplant outcomes

35. Poster session: Dobutamine stress echo

36. (169) Incidence and Predictors of Vasoplegia after Heart Transplantation: Results from the International PGD Consortium

39. Pulmonary hypertension and congenital heart disease: medical treatment and risk factors for survival

41. Evaluation of left ventricular diastolic function in Marfan syndrome using speckle-tracking echocardiography

42. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

43. Potential Role of Donor-Derived Cell Free DNA as a New Biomarker in Cardiac Allograft Vasculopathy (FreeDNA-CAV)

44. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness

45. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

47. Current Situation and Prognostic Evolution of Combined Heart-lung Transplantation in a European Union Country.

48. Spanish Heart Transplant Registry. 31th Official Report of the Heart Failure Association of the Spanish Society of Cardiology

49. Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure

50. Use of Intra-aortic Balloon Pump as a Bridge to Heart Transplant in Spain: Results From the ASIS-TC Study

Catalog

Books, media, physical & digital resources